Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death. Liraglutide is a human glucagon-like peptide receptor analog approved for use in patients with type 2 diabetes mellitus (T2DM).
were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM. (Am Heart J 2013; 166:823-830.e5.) Background Diabetes mellitus affects nearly 350 million people worldwide, 1 
including 26 million patients in the United
States, 2 and the prevalence continues to increase. Diabetes is a chronic disease associated with long-term vascular complications. Type 2 diabetes mellitus (T2DM) is a multisystem disorder that is also independently associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease (CHD), stroke, and cardiovascular death. Subgroups of individuals with diabetes at lower absolute risk of cardiovascular complications, including women, younger persons, nonsmokers, and persons with below average blood pressure, also have an elevated risk of micro-and macrovascular complications (including CHD), compared with persons without diabetes. 3 Effective strategies to mitigate cardiovascular risk and prevent or reduce the occurrence of microvascular complications are the cornerstone of treatment for patients with diabetes. 4 These measures include lifestyle management, smoking cessation, and individualized risk factor treatment for low-density lipoprotein cholesterol and blood pressure. Glycemic control significantly reduces the development and progression of microvascular complications. Although metformin is the mainstay of initial therapy, treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist is now regularly used as an addon approach to achieve glycemic control. 5 Although available diabetes therapies clearly improve glycemic control, the cardiovascular safety of particular glucose-lowering agents is controversial. When cardiovascular safety concerns were identified in an agonist of the peroxisome proliferator-activated receptor gamma class, 6 as well as in a separate federally funded study examining tight glycemic control in general, 7 the United States Food and Drug Administration subsequently issued mandatory guidelines to manufacturers for evaluating the cardiovascular safety of emerging therapies to treat diabetes. 8 Before new diabetes drug approval, manufacturers are now required to perform an integrated meta-analysis of completed studies to demonstrate an estimated relative risk with upper two-sided 95% confidence limits for major adverse cardiovascular events of b1.8 versus comparators. If the upper limit is 1.3 to 1.8, safety must subsequently be demonstrated in postmarketing cardiovascular outcome trials to rule out an upper confidence limit of 1.3.
Glucagon-like peptide-1 and liraglutide. Native GLP-1 is an incretin hormone produced in the gut and secreted in response to food consumption. 9 The main pharmacological effects of GLP-1 are stimulation of endogenous insulin in response to elevated glucose, suppression of elevated glucagon, and regulation of satiety/appetite 10, 11 and are all potentially beneficial or impaired in T2DM.
Liraglutide is an analog of human GLP-1 approved for use in patients with T2DM. Liraglutide has 97% homology with human GLP-1 and is administered subcutaneously once daily. Its glucose-lowering efficacy has been established, and its use results in hemoglobin A1c (HbA1c) reductions of 1.0 to 1.5% in addition to moderate weight loss across a wide range of patient types. 12 To formally assess the cardiovascular safety of liraglutide, the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial (clinicaltrials.gov NCT01179048) was commenced in 2010. This article reports the study design and baseline characteristics of the study population.
Study design
Objective. The primary objective of LEADER is to assess the effect of treatment with liraglutide compared to placebo (for at least 3.5 years and up to 5 years) on the incidence of cardiovascular events, as defined by the primary end point of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke in adult patients with T2DM. The primary analysis will be noninferiority testing. If the prespecified noninferiority criteria are met, then superiority testing will be performed. Noninferiority of liraglutide versus placebo will be assessed by inspecting the upper range of the twosided 95% CI, and noninferiority will be established if that upper range is b1.3. Only if noninferiority is established for the primary outcome will the data then be used to test for evidence of a lower outcome hazard with liraglutide over placebo. Superiority will be established if the hazard ratio of the upper range of the two-sided 95% CI is b1.0. This approaches a closed testing procedure, and therefore, no adjustment of the significance level is required.
Patient population. LEADER is a phase 3B, multicenter, international, randomized, double-blind, placebo-controlled clinical trial with long-term follow-up ( Figure 1 ). Male and female patients with T2DM, who were either drug naive or treated with oral antihyperglycemic agents or selected insulin regimens (human NPH, long-acting analog, or premixed) alone or in combination with oral antihyperglycemics were eligible for inclusion.
LEADER enrolled 2 distinct populations of high-risk patients either with or without prior cardiovascular disease (CVD): (1) patients with prior CVD were ≥50 years old and had one or more of the following cardiovascular comorbidities (detailed criteria are shown in Table I ): concomitant CVD, cerebrovascular disease, peripheral vascular disease, chronic renal failure, or chronic heart failure; (2) patients without prior CVD were ≥60 years old at screening and had one or more cardiovascular risk factors shown in Table I equation was also prespecified. Exclusion criteria are listed in Table I .
Treatment regimen. After eligibility assessment and informed consent, patients completed a minimum 2-week run-in period consisting of a daily single-blind subcutaneous injection of placebo. Patients demonstrating ≥50% adherence to the regimen and willingness to continue with the injection protocol throughout the trial then underwent randomization, which was carried out for all subjects using the interactive voice/web response system. Subjects meeting all inclusion/exclusion criteria were randomized in a 1:1 manner to receive a doubleblind, once-daily maximum dose of liraglutide 1.8 mg or equivalent placebo as an add-on to their standard-of-care treatment. Liraglutide was administered at 0.6 mg daily for 1 week, 1.2 mg for an additional week, and a potential maximum dosage thereafter of 1.8 mg based on tolerance, as determined by the investigator.
For patients with suboptimal glucose control after randomization, concomitant use and dosage of insulin, sulfonylureas, glimepiride, thiazolidinediones, and α-glucosidase inhibitors is permitted at the discretion of the investigator, but use of other GLP-1 agonists, dipeptidyl peptidase-4 inhibitors, and pramlintide is not.
Concomitant use of premixed insulin. Continued use of premixed insulin, including injection frequency and timing, during the trial is permitted at the investigator's discretion. A 20% reduction in insulin dosage when starting randomized therapy is recommended for patients with HbA1c ≤8%.
The LEADER global expert panel (GEP) and national study leaders in participating countries developed a protocol for the treatment of risk factors and concomitant use of medications. Guidelines were finalized during a series of workshops using consensus practice recommendations in 2010. [13] [14] [15] [16] Table II contains a list of the finalized standard of care guidelines endorsed by the LEADER steering committee.
Planned follow-up. After randomization, patients were initially seen at 1, 3, and 6 months. Thereafter, patients are seen every 6 months for up to 5 years. During each study visit, patients are assessed for clinical events, study drug compliance, and concomitant medication 
Inclusion criteria
• Type 2 diabetes • Anti-diabetic drug naïve or treated with one or more oral anti-diabetic drugs or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s) • HbA1c ≥7.0% • Prior CVD cohort: age ≥50 and ≥1 of the following criteria. ○ Prior MI ○ Prior stroke or TIA ○ Prior coronary, carotid or peripheral arterial revascularization ○ N50% stenosis of coronary, carotid, or lower extremity arteries ○ History of symptomatic CHD documented by Positive exercise stress test or any cardiac imaging or Unstable angina with ECG changes ○ Asymptomatic cardiac ischemia Documented by positive nuclear imaging test, exercise test or dobutamine stress echo ○ Chronic heart failure NYHA class II-III ○ Chronic renal failure, eGFR b60 mL/min per 1. usage. Blood, urine specimens, and electrocardiograms were collected at randomization and then yearly for the duration of the study.
End points. The primary end point is the time from randomization to a composite outcome consisting of the first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke. Comprehensive descriptions for each component of the primary composite end point are listed in the online Appendix Supplementary Table I. Secondary end points include the first occurrence of an expanded composite cardiovascular outcome, including cardiovascular death, nonfatal MI, nonfatal stroke, revascularization, hospitalization for unstable angina, or hospitalization for chronic heart failure. Additional end points include time from randomization to the occurrence of noncardiovascular or all-cause death, each individual component of the expanded composite cardiovascular outcome, composite microvascular outcomes, and each individual component of composite microvascular outcomes.
Safety end points. Additional end points are being assessed to support the secondary efficacy and safety objectives (online Appendix Supplementary Table II) . Hypoglycemia is defined according to American Diabetes Association criteria 17 as (1) severe: requiring the assistance of another person to administer resuscitative actions, carbohydrate, or glucagon; (2) documented symptomatic: typical symptoms of hypoglycemia accompanied by a measured plasma glucose concentration ≤70 mg/dL; (3) asymptomatic: measured plasma glucose concentration ≤70 mg/dL in the absence of symptoms; (4) probable symptomatic: unmeasured plasma glucose concentration in the presence of typical symptoms of hypoglycemia; and (5) relative hypoglycemia: typical symptoms of hypoglycemia and interpreted by the patient as a hypoglycemic episode with a measured plasma glucose concentration ≥70 mg/dL. An independent, event adjudication committee (EAC) blinded to treatment arm will adjudicate serious adverse events, including pancreatitis or severe persistent abdominal pain leading to suspicion of pancreatitis, neoplasm, and thyroid disease resulting in thyroidectomy (online Appendix Supplementary Table II) .
Calcitonin monitoring. Blood samples were collected at screening to assess baseline levels of calcitonin in a central laboratory; patients with values ≥50 ng/L were excluded. Calcitonin levels are measured at prespecified time intervals in all subjects throughout the study. An independent calcitonin-monitoring committee (CMC) consisting of thyroid experts blinded to treatment provides ongoing surveillance to monitor longitudinal changes in calcitonin levels. Any value ≥20 ng/L is reported to the CMC for review and consideration of additional diagnostic procedures. For any level ≥20 ng/L, testing is repeated within 4 weeks. If the level is confirmed, a medical event of special interest is reported, and the CMC provides guidance on individualized follow-up and/or subsequent monitoring to site investigators. All medical events of special interest, including development of neoplasm or thyroid disease resulting in thyroidectomy, are reviewed and adjudicated by the EAC.
Study organization, event adjudication, and data monitoring. LEADER is overseen by a steering committee composed of experts in endocrinology, cardiology, gastroenterology, thyroid disease, nephrology, biostatistics, and employees of the study sponsor (Novo Nordisk). The steering committee independently oversees all aspects of the trial. The GEP consists of principal investigators from enrolling countries and designated employees of the sponsor and provides advice and active implementation assistance for operational issues.
Several end points will be adjudicated by the EAC based on several efficacy end points, including death, acute coronary syndrome (MI and hospitalization for unstable angina), cerebrovascular events (stroke and transient ischemic attack), coronary revascularization procedures, hospitalization for heart failure, nephropathy, and diabetic retinopathy.
The EAC consists of experts in cardiology, neurology, gastroenterology, endocrinology, oncology, pathology, nephrology, and ophthalmology and will meet throughout the duration of the trial. A chairperson oversees 4 separate subcommittees consisting of 16 primary adjudicators. The cardiovascular subcommittee includes 2 cardiologists and 2 neurologists. The microvascular subcommittee includes 2 nephrologists and 2 ophthalmologists. The pancreatitis subcommittee includes 3 gastroenterologists. The neoplasm subcommittee includes 3 oncologists and 2 endocrinologists. In case of thyroid disease resulting in a thyroidectomy, adjudicators include 1 endocrinologist and 1 oncologist who will review both the local pathology report and the report of an external pathologist who has reviewed the pathology specimen independently.
An independent, external data-monitoring committee (DMC) was established to perform ongoing safety surveillance and consists of permanent members who are recognized experts in cardiology, endocrinology, gastroenterology, and statistics. The DMC has access to complete unblinded data and meets at predefined intervals and on an ad hoc basis as required to evaluate all relevant safety information. After each meeting, the DMC will issue a recommendation on trial continuation, modification, or termination. The DMC can recommend to terminate the trial prematurely in case there is evidence for an excess number of deaths in the liraglutide group (significance level determined at P b .01), an excess number of major adverse cardiovascular events in the liraglutide group (significance level determined at P b .01), or clear evidence of benefit for the primary end point in the liraglutide arm (significance level determined at P b .001).
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Statistical considerations
Sample size calculation. The required sample size was estimated on the basis of time to first primary outcome using a log-rank test that included the full analysis set and an intention-to-treat principle. The primary event rate was estimated to be 1.8% in both the liraglutide and placebo groups, with uniform enrollment over 1.5 years, and a maximum follow-up period of 5 years. The noninferiority margin was set at 1.3 for the upper bound of the 2-sided 95% CI. It was also estimated that patients who permanently stop randomized treatment and are lost to follow-up would not exceed 10% in total. Finally, the power to reject the null hypothesis (ie, that the upper bound of the 2-sided CI would exceed 1.3) was set at 90%. Given these assumptions, 8,754 randomized subjects were required with an accrual of no b611 events with a minimum follow-up of 42 months after last subject randomized.
Analysis of the primary end point. Only outcomes confirmed by the blinded EAC will be analyzed. Subjects who complete or discontinue the trial without having an outcome will be censored for the relevant analyses on the last day of follow-up. The primary end point will be analyzed for the full analysis set and performed using Cox regression, including only treatment group as a covariate. The Cox regression model will be used to estimate the hazard ratio (liraglutide to placebo) and the 2-sided 95% CI. The objective of the LEADER trial is to assess the cardiovascular safety of liraglutide. Safety will be established if the two-sided 95% confidence limit is less than the prespecified upper bound of 1.3, as established by the United States Food and Drug Administration. If safety is established, then formal superiority testing will be performed. Noninferiority of liraglutide versus placebo will be assessed and established if the upper limit is b1.3. If noninferiority is established for the primary outcome, the data will be used to test for evidence of a lower outcome hazard with liraglutide versus placebo. Superiority with respect to the hazard ratio will be established if the upper range Enrollment of LEADER trial participants by country. Data presented are number of randomized participants/number of trial sites that randomized participants by country. In total, 9,340 participants were randomized across 410 active LEADER trial sites. There were 7 sites that screened but did not enroll or randomize any participants.
of the two-sided 95% CI is b1. This approach is a closed testing procedure, and therefore, no adjustment of the significance level is required. 18, 19 Exploratory subgroup analyses. The effect of sex, age (b60 or ≥60 years), body mass index (≤30or N30 kg/ m 2 ), HbA1c (≤8.3 or N8.3%), duration of diabetes (≤11 or N11 years), region (Europe, North America, Asia, or other), race (white, black, Asian, or other), cardiovascular risk, chronic heart failure, severe chronic renal failure, severe-to-moderate chronic renal failure, and use of concomitant glucose medication and/or insulin on the primary composite end point will be explored separately as a main effect and interaction with treatment by adding each to the original model.
There will be 2 populations analyzed. The full analysis set includes all randomized subjects with evaluation by intention-to-treat, and subjects will be evaluated as randomized. A sensitivity analysis will be performed using the per-protocol analysis set that includes only data from follow-up of subjects exposed to treatment plus 30 days. Subjects exposed to treatment in the per-protocol analysis will include those with a maximum accumulated drug holiday of ≤120 days during the study. Subjects accumulating N120 days will be Data presented as number (percentage of group) or mean ± SD. ⁎ Not used in combination with insulin. † Either used alone or in combination with concomitant oral antihyperglycemics.
considered as having discontinued study drug on the 121st day.
Enrolled population
Enrollment for LEADER commenced in September 2010 and concluded in April 2012. Patients were enrolled at 410 sites in 32 countries (Figure 2) . Baseline demographics of the enrolled population are shown in Table III . Of the 9,340 patients, 7,592 (81.3%) had prior CVD and 1,748 (18.7%) did not. There were 1,854 patients with moderate and 177 with severe reductions in screening eGFR.
Discussion
There remains a compelling need to develop novel, effective, and safe glucose-lowering therapies for patients with T2DM. Liraglutide is associated with a reduction in HbA1c ranging from 1.0 to 1.5%. 20 Current dosing of liraglutide was derived from clinical data aiming to improve gastrointestinal tolerability while maintaining efficacy. From this perspective, a starting dose of 0.6 mg daily is suggested, increasing to 1.2 or 1.8 mg based on clinical response.
Prior studies have investigated the perceived beneficial effects of GLP-1 receptor agonists on cardiovascular risk. The mechanism of action behind these effects remains to be clarified. However, there appear to be a number of direct and indirect effects of treatment possibly explaining this reduction in risk, such as significant weight and systolic blood pressure reduction and, potentially, direct effects on cardiac myocytes and endothelium. 21 A decrease in systolic blood pressure of 2.1 mm Hg with liraglutide 1.2 mg and 3.6 mm Hg with 1.8 mg, together with a sustained mean weight loss of approximately 2 kg, has been reported. 22 In addition, data from 5 longterm phase 3 trials suggested no adverse impact of liraglutide treatment on lipid profiles with respect to cardiovascular risk and favorable changes in triglycerides and free fatty acids. Others have reported decreases in levels of cardiovascular risk markers such as plasminogen-activator inhibitor-1 and B-natriuretic peptide after treatment. [23] [24] [25] However, liraglutide is associated with an approximate 1-2 beat/min increase in heart rate.
Conclusions
LEADER is a phase 3B randomized, double-blind clinical trial to evaluate the cardiovascular safety of liraglutide in patients with T2DM at heightened risk for cardiovascular complications. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to standard of care for a global population of patients with T2DM. Dr Pocock reports receiving honoraria for serving on independent data monitoring committees for the EXSCEL, TECOS, and ACE trials.
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• Non-ST-elevation MI: At the J point in 2 contiguous leads (≥0.2 mV in men or ≥0. 15 (2) ST depression and T-wave changes New horizontal or down-sloping ST depression ≥0.05 mV in 2 contiguous leads; and/or T inversion ≥0.1 mV in 2 contiguous leads with prominent R wave or R/S ratio N1. † Pathological Q waves: (1) Any Q wave in leads V2-V3 ≥0.02 s or QS complex in leads V2 and V3 Q wave ≥0.03 s and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any 2 leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF).
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